HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, R. N. Search for Related Content PubMed PubMed Citation Articles by Jones, R. N.

Resistance Patterns Among Nosocomial Pathogens^*

Trends Over the Past Few Years

^* From the Department of Pathology, University of Iowa College of Medicine, Iowa City, IA.

Correspondence to: Ronald N. Jones, MD, The Jones Group, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317

Multiple surveillance studies have demonstrated that resistance among prevalent pathogens is increasing at an alarming rate, leading to greater patient morbidity and mortality from nosocomial infections. Among Gram-positive organisms, the most important resistant pathogens are methicillin- (oxacillin-)resistant Staphylococcus aureus, ß-lactam-resistant and multidrug-resistant pneumococci, and vancomycin-resistant enterococci. Important causes of Gram-negative resistance include extended-spectrum ß-lactamases (ESBLs) in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis, high-level third-generation cephalosporin (Amp C) ß-lactamase resistance among Enterobacter species and Citrobacter freundii, and multidrug-resistance genes observed in Pseudomonas aeruginosa, Acinetobacter, and Stenotrophomonas maltophilia. In selecting an empiric treatment for a nosocomial infection, one should consider the prevalent resistance patterns. Antimicrobials used for the treatment of nosocomial infections should be effective against any likely resistant pathogens and should not further promote the development of resistance. Recent data suggest that because of ESBLs and high-level amp C ß-lactamase resistances, use of third-generation cephalosporins may be ineffective in many patients with nosocomial infections. In addition, use of these agents may allow overgrowth of inherently resistant enterococci. The role of fluoroquinolones in the empiric treatment of nosocomial infections is also being limited by new resistance patterns and increasing resistance levels. Available antimicrobials with good activity against many resistant pathogens include the carbapenems, piperacillin/tazobactam, and cefepime. In addition, several new agents with good activity against Gram-positive organisms are in development or have been recently released. Appropriate antimicrobial selection, surveillance systems, and effective infection-control procedures are key partners in limiting antimicrobial-resistant pathogen occurrence and spread.

Key Words: antibiotic resistance • antibiotics • cephalosporins • enterococci • fluoroquinolones • methicillin-resistant Staphylococcus aureus • nosocomial infections • penicillins • pneumococci

This article has been cited by other articles:

				L. E. Morrow and A. F. Shorr Not Everything That Can Be Counted Counts ... Chest, February 1, 2008; 133(2): 336 - 337. [Full Text] [PDF]

				J. Li, C. R. Rayner, R. L. Nation, R. J. Owen, D. Spelman, K. E. Tan, and L. Liolios Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 2946 - 2950. [Abstract] [Full Text] [PDF]

				Y. Ueda, K. Kanazawa, K. Eguchi, K. Takemoto, Y. Eriguchi, and M. Sunagawa In Vitro and In Vivo Antibacterial Activities of SM-216601, a New Broad-Spectrum Parenteral Carbapenem Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4185 - 4196. [Abstract] [Full Text] [PDF]

				G. A. Pankey Tigecycline J. Antimicrob. Chemother., September 1, 2005; 56(3): 470 - 480. [Abstract] [Full Text] [PDF]

				M. D. Navarro-Martinez, E. Navarro-Peran, J. Cabezas-Herrera, J. Ruiz-Gomez, F. Garcia-Canovas, and J. N. Rodriguez-Lopez Antifolate Activity of Epigallocatechin Gallate against Stenotrophomonas maltophilia Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2914 - 2920. [Abstract] [Full Text] [PDF]

				E. M. Graffunder, K. E. Preston, A. M. Evans, and R. A. Venezia Risk factors associated with extended-spectrum {beta}-lactamase-producing organisms at a tertiary care hospital J. Antimicrob. Chemother., July 1, 2005; 56(1): 139 - 145. [Abstract] [Full Text] [PDF]

				D. K Farver, D. D Hedge, and S. C Lee Ramoplanin: A Lipoglycodepsipeptide Antibiotic Ann. Pharmacother., May 1, 2005; 39(5): 863 - 868. [Abstract] [Full Text] [PDF]

				A. L Quinn, J. P Parada, J. Belmares, and J P. O'Keefe Intrathecal Colistin and Sterilization of Resistant Pseudomonas aeruginosa Shunt Infection Ann. Pharmacother., May 1, 2005; 39(5): 949 - 952. [Abstract] [Full Text] [PDF]

				D. Berlana, J. M. Llop, E. Fort, M. B. Badia, and R. Jodar Use of colistin in the treatment of multiple-drug-resistant gram-negative infections Am. J. Health Syst. Pharm., January 1, 2005; 62(1): 39 - 47. [Abstract] [Full Text] [PDF]

				M. Rahman, I. Kuhn, M. Rahman, B. Olsson-Liljequist, and R. Mollby Evaluation of a Scanner-Assisted Colorimetric MIC Method for Susceptibility Testing of Gram-Negative Fermentative Bacteria Appl. Envir. Microbiol., April 1, 2004; 70(4): 2398 - 2403. [Abstract] [Full Text] [PDF]

				L. Tan, X. Sun, X. Zhu, Z. Zhang, J. Li, and Q. Shu Epidemiology of Nosocomial Pneumonia in Infants After Cardiac Surgery Chest, February 1, 2004; 125(2): 410 - 417. [Abstract] [Full Text] [PDF]

				H. S. Sader, D. M. Johnson, and R. N. Jones In Vitro Activities of the Novel Cephalosporin LB 11058 against Multidrug-Resistant Staphylococci and Streptococci Antimicrob. Agents Chemother., January 1, 2004; 48(1): 53 - 62. [Abstract] [Full Text] [PDF]

				E.-W. Lee, M. N. Huda, T. Kuroda, T. Mizushima, and T. Tsuchiya EfrAB, an ABC Multidrug Efflux Pump in Enterococcus faecalis Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3733 - 3738. [Abstract] [Full Text] [PDF]

				K. Maquelin, C. Kirschner, L.-P. Choo-Smith, N. A. Ngo-Thi, T. van Vreeswijk, M. Stammler, H. P. Endtz, H. A. Bruining, D. Naumann, and G. J. Puppels Prospective Study of the Performance of Vibrational Spectroscopies for Rapid Identification of Bacterial and Fungal Pathogens Recovered from Blood Cultures J. Clin. Microbiol., January 1, 2003; 41(1): 324 - 329. [Abstract] [Full Text] [PDF]

				C. von Eiff and G. Peters Comparative in vitro activity of ABT-773 and two macrolides against staphylococci J. Antimicrob. Chemother., January 1, 2002; 49(1): 189 - 192. [Abstract] [Full Text] [PDF]

				S. Roychoudhury, T. L. Twinem, K. M. Makin, M. A. Nienaber, C. Li, T. W. Morris, B. Ledoussal, and C. E. Catrenich Staphylococcus aureus Mutants Isolated via Exposure to Nonfluorinated Quinolones: Detection of Known and Unique Mutations Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3422 - 3426. [Abstract] [Full Text] [PDF]